Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

AbbVie Submits FDA Application For Etentamig In Multiple Myeloma

27 October 2026 · By · Wire by Fusion42

Published

27 October 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 27 October 2026 · Fusion42 review

AbbVie has submitted an application to the US FDA seeking approval for Etentamig to treat multiple myeloma, aiming to expand its therapeutic options in oncology.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

Founders working on oncology drugs must track AbbVie's new FDA bid as it redefines the competitive field for multiple myeloma treatments. Your product positioning might need adjustment before this drug impacts the market.

◆ Coverage

1 source · 27 Oct 2026

◆ Related on Wire

◆ Topics

Drug Discoveryabbviefda-applicationmultiple-myelomadrug-approvaloncology